Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Receivables (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Change in Receivables readings, the most recent being -$38.4 million for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 1820.0% to -$38.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $210.5 million, a 428.89% increase, with the full-year FY2025 number at $210.5 million, up 428.89% from a year prior.
  • Change in Receivables hit -$38.4 million in Q4 2025 for Neurocrine Biosciences, down from $132.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $132.3 million in Q3 2025 to a low of -$38.4 million in Q4 2025.
  • Median Change in Receivables over the past 5 years was $19.5 million (2023), compared with a mean of $26.5 million.
  • Biggest five-year swings in Change in Receivables: skyrocketed 10750.0% in 2021 and later tumbled 1820.0% in 2025.
  • Neurocrine Biosciences' Change in Receivables stood at $21.7 million in 2021, then skyrocketed by 114.29% to $46.5 million in 2022, then crashed by 53.98% to $21.4 million in 2023, then plummeted by 109.35% to -$2.0 million in 2024, then tumbled by 1820.0% to -$38.4 million in 2025.
  • The last three reported values for Change in Receivables were -$38.4 million (Q4 2025), $132.3 million (Q3 2025), and $79.7 million (Q2 2025) per Business Quant data.